PKI 402

04/01/2010 - "Preferential accumulation of PKI-402 in tumor tissue was observed. "
04/01/2010 - "In MDA-MB-361 tumors, PKI-402 (100 mg/kg, single dose) suppressed Akt phosphorylation (at T308) and induced cleaved PARP. "
04/01/2010 - "In MDA-MB-361, PKI-402 at 100 mg/kg (daily for 5 days, one round) reduced initial tumor volume of 260 mm(3) to 129 mm(3) and prevented tumor regrowth for 70 days. "
04/01/2010 - "In vivo, PKI-402 inhibited tumor growth in MDA-MB-361, glioma (U87MG), and lung (A549) xenograft models. "
09/01/2020 - "Therefore, determining the role of dual PI3K/mTOR inhibitors PKI-402 in cancer cells may facilitate overcoming chemoresistance. "

01/01/2019 - "In this study, we showed that treatment of PKI-402 led to significant decreases in RANKL-induced osteoclastogenesis and osteoclast-specific gene expression in mouse bone marrow-derived macrophages and reduced proliferation, migration and invasion of MDA-MB-231 breast cancer cells by blocking the PI3K-AKT-mTOR signaling pathway. "
01/01/2023 - "Clonogenic assay results showed that PKI-402 plus IR inhibited the colony formation ability of MCF-7 and breast cancer stem cell lines. "
01/01/2023 - "The effects of PKI-402 on breast tumor models' radiosensitivity via dual inhibition of PI3K/mTOR."
01/01/2019 - "These results strongly suggest that PKI-402 might have a therapeutic potential to inhibit breast cancer induced osteolysis."
01/01/2019 - "However, the role of PKI-402 involved in osteolysis induced by breast cancer remains unclear. "

09/01/2020 - "Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy."

01/01/2019 - "These results strongly suggest that PKI-402 might have a therapeutic potential to inhibit breast cancer induced osteolysis."
01/01/2019 - "However, the role of PKI-402 involved in osteolysis induced by breast cancer remains unclear. "
01/01/2019 - "Importantly, as evidenced by the observation that the administration of PKI-402 inhibited MDA-MB-231-induced osteolysis in vivo, PKI-402 exerted an inhibitory effect on osteoclast formation and bone resorption, critical for cancer cells-induced bone destruction. "
01/01/2019 - "Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis."

04/01/2010 - "In vivo, PKI-402 inhibited tumor growth in MDA-MB-361, glioma (U87MG), and lung (A549) xenograft models. "
04/01/2010 - "PKI-402 inhibited growth of human tumor cell lines derived from breast, brain (glioma), pancreas, and non-small cell lung cancer tissue and suppressed phosphorylation of PI3K and mTOR effector proteins (e.g., Akt at T308) at concentrations that matched those that inhibited cell growth. "